August 3, 2007 - ART Advanced Research Technologies Inc. (ART), a Canadian medical device company, announced an agreement to develop and conduct clinical research with the Stanford Breast Imaging Section of Stanford University to evaluate the effectiveness of the SoftScan optical breast imaging system in treatment monitoring and diagnosis of breast cancer.
The SoftScan optical breast imaging system has been designed as a complementary diagnostic tool to mammography, with ultimate uses in the detection and treatment monitoring of breast cancer. Its noninvasive, painless approach uses time-domain optical Imaging Technology, which may allow clinicians to better locate and characterize breast tumors as benign or malignant and could reportedly provide faster assessment of therapeutic effectiveness. Unlike mammography whose use must be strictly limited, SoftScan emits no radiation and can be safely used as often as needed to monitor patients. The device was created and developed by ART Advanced Research Technologies Inc., and has obtained regulatory approvals for its commercialization in Canada and in Europe.
Dr. Debra Ikeda, Director of the Stanford Breast Imaging Section, is the Principal Investigator of this clinical research collaboration. In this role, she will also lead collaborative initiatives with Dr. Sanjiv Sam Gambhir, Director, Molecular Imaging Program at Stanford. The primary objective will be to extend SoftScan's clinical value into the expanding field of breast cancer probe development.
"We look forward to clinical research with SoftScan optical breast imaging to address important unmet needs in breast cancer treatment monitoring and diagnosis. In addition, we look forward to incorporating molecular imaging techniques developed at the Clark Center into our breast cancer research," stated Dr. Ikeda, Director of the Stanford University Breast Imaging Section.